By Brian Crawford, VP of Operations at Asahi Kasei Bioprocess America
As demand begins to level out in the aftermath of the COVID-19 pandemic, drug manufacturers and suppliers are collaborating to build a new set of standard operating procedures across the industry. The pandemic had a widespread and well-known impact on raw materials and labor that delayed supply chains globally. In the bioprocessing industry, companies fast-tracked projects to help combat the pandemic; as a result, demand for single-use components skyrocketed as raw materials and labor forces dwindled.
It is crucial to reframe expectations from how the supply chain existed pre-pandemic to how it will function going forward. Just-in-time manufacturing strategies are no longer suitable for maintaining efficient, reliable timelines; instead, suppliers must consider holding higher levels of inventory and increasing production capacity. Download the full article to learn more about how customers, suppliers, and sub-suppliers are utilizing enhanced forecasting and collective problem-solving efforts to prepare adaptive supply chain strategies.